CPAP Does Not Reduce Inflammatory Biomarkers in Patients With Coronary Artery Disease and Nonsleepy Obstructive Sleep Apnea: A Randomized Controlled Trial

Thunstrom E., Glantz H., Yucel-Lindberg T., Lindberg K., SAYGIN M. , Peker Y.

SLEEP, vol.40, no.11, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 11
  • Publication Date: 2017
  • Doi Number: 10.1093/sleep/zsx157
  • Title of Journal : SLEEP
  • Keywords: continuous positive airway pressure, coronary artery disease, obstructive sleep apnea, interleukin-6, interleukin-8, tumor necrosis factor-alpha, C-REACTIVE PROTEIN, POSITIVE AIRWAY PRESSURE, CARDIOVASCULAR RISK-FACTORS, INTERLEUKIN-6, EVENTS, PREDICTORS, THERAPY, MARKERS


Objectives: Obstructive sleep apnea (OSA) and enhanced vascular inflammation coexist in patients with coronary artery disease (CAD). Continuous positive airway pressure (CPAP) is first-line treatment for OSA with daytime sleepiness. This analysis of data from the RICCADSA (Randomized Intervention with CPAP in Coronary Artery Disease and Sleep Apnea) trial investigated the effects of CPAP on inflammatory markers in patients with CAD and nonsleepy OSA.